CD155 in Bladder Cancer

Recruiting

• Conditions: Bladder Cancer
• Interventions: Drug: Adjuvant chemotherapy

• Registration Number: NCT03789682
• Lead Sponsor: Fudan University

Brief Summary

This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-01-01
• Study First Submitted: 2018-12-27
• Study First Submitted QC: 2018-12-27
• Study First Posted: 2018-12-28
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-03
• Last Update Posted: 2020-02-05
• Primary Completion: 2023-01-01
• Study Completion: 2028-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• patients with non-metastatic muscle invasive bladder cancer
• pathology confirmed urothelial carcinoma
• underwent cystectomy and pelvic lymph node dissection

Read More

Exclusion Criteria

• not enough tissue for immunohistochemistry
• patients with a second neoplasm

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
FUSCC cystectomy cohort	Adjuvant chemotherapy	patients underwent cystectomy in Fudan University Shanghai Cancer Center

Primary Outcome Measures

Name	Time	Method
Recurrence free survival	2018.1.1-2023.12.31	Time to recurrence or metastasis

Secondary Outcome Measures

Name	Time	Method
Overall survival	2018.1.1-2028.1.1	Time to death
Benefit from adjuvant chemotherapy	2018.1.1-2028.1.1	Survival analysis grouped by adjuvant chemotherapy
Benefit from neoadjuvant chemotherapy	2018.1.1-2028.1.1	response to neoadjuvant chemotherapy

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China